Han-Joo Kim

Han-Joo Kim

Company: Imnewrun Biosciences Inc.

Job title: Chief Executive Officer


TRANSMAB:PD-L1 – a Novel Therapeutic Strategy Targeting Reactive Astrocytes & Glial Checkpoint in Alzheimer’s Disease 1:45 pm

• Outlining the role of GFAP+ astrocytes in the neuroinflammatory cascade in neurodegeneration • Exploring PD-L1+ GFAP+ astrocyte and PD-1+ microglia as a glial checkpoint and a potential novel therapeutic target against Alzheimer’s Disease • Showcasing TRANSMAB:PD-L1 antibody ability to cross the BBB, reduce GFAP, and improve pathological outcome in preclinical AD modelsRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.